Skip to main content

Table 4 Disposition of polymorphisms involved in nevirapine metabolism

From: Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy

  Total Hepatotoxicity No hepatotoxicity p*
n = 362 n = 8 n = 354
ABCB1 c.3435/rs1045642, n (%)     0.019
 CC 86 (23.8) 5 (5.8) 81 (94.2)  
 CT 178 (49.2) 1 (0.6) 177 (99.4)  
 TT 98 (27.0) 2 (2.0) 96 (98.0)  
CYP2B6 c.516/rs3745274, n (%)     0.706
 GG 196 (54.1) 6 (3.1) 190 (96.9)  
 GT 141 (39.0) 2 (1.4) 139 (98.6)  
 TT 25 (6.9) 0 (0.0) 25 (100.0)  
CYP3A4/A5 **, n (%)     0.602
Extensive 58 (16.1) 0 (0.0) 58 (100.0)  
Intermediate 270 (74.5) 8 (3.0) 262 (97.0)  
Poor 25 (6.9) 0 (0.0) 25 (100.0)  
 nd 9 (2.5) 0 (0.0) 9 (100.0)  
  1. Abbreviations: n number, nd not determined, ABCB ATP Binding Cassette Subfamily B, CYP Cytochrome P450 enzyme
  2. *χ2 test ** CYP3A4*22/rs35599367 and CYP3A5*3/rs776746 combined genotypes for comprehensive functional evaluation [33, 34]